Project Grant R43CA287873
Award Date
9/19/24
Completion Date
8/31/25
Dollars Obligated
$371K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Houston, TX 77021, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...
This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a short RNA therapeutic to treat ovarian cancer at Nuago Therapeutics Inc. in Chicago, IL. The award will fund research to create a novel, targeted therapy that aims to induce DNA damage in ovarian cancer cells. This project, running from June 2025 through May 2026, seeks to advance a potential new treatment approach that could improve outcomes for...
This Cooperative Agreement award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $1,000,000.00 in funding to Window Therapeutics, Inc. to develop a novel class of antibody-drug conjugates (ADCs) for treating metastatic cancer. The project aims to significantly increase the drug-to-antibody ratio of ADCs, allowing for the use of less toxic, yet more effective, cancer-killing drugs to be delivered directly to tumor cells. The goal is to...
This federal Project Grant award for $716,314.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop novel therapeutics targeting FGFR2 alterations in gastroesophageal adenocarcinoma (GEA). The key products and services to be delivered include: Utilizing novel immune-competent mouse models of FGFR2-altered GEA to develop and test highly efficacious FGFR2 biparatopic antibodies (BIPABs) and FGFR2-targeted antibody-drug conjugates (ADCs), alone or in...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $215,311 to the University of Texas Health Science Center at Houston to develop and evaluate antibody-drug conjugates (ADCs) that target the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) Generate GPR56-targeted ADCs by attaching various cytotoxic drugs and assess their cell-killing potency in TNBC cell lines; 2) Evaluate the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
The National Cancer Institute (NCI) awarded a $798,512 Project Grant under CFDA 93.395 - Cancer Treatment Research to Luminary Therapeutics, Inc., a small disadvantaged business, to develop an allogeneic gamma/delta armored dual-targeting chimeric antigen receptor (CAR) T-cell therapy to treat epithelial ovarian carcinoma. The project aims to address key challenges with CAR T-cell therapies against solid tumors, including antigen escape and the immunosuppressive tumor microenvironment, through...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $863,708 to Mirecule, Inc. to develop an antibody-oligonucleotide conjugate therapy for treating head and neck squamous cell carcinoma. The award period runs from September 18, 2024 to August 31, 2026. The key products or services to be delivered under this award include: 1) validating the efficacy of the MC-30 antibody-RNA conjugate in preclinical cancer models, 2) executing...
This federal Project Grant award of $412,429 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate novel approaches to overcome drug resistance in high-grade serous ovarian cancer (HGSOC). The award aims to demonstrate that combining the drug clofarabine with either a PARP inhibitor or an ATR inhibitor can sensitize CCNE1-driven tumors to these therapies by inducing replication stress through nuclear translocation of the protein cathepsin...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $400,000 to Senex Biotechnology Inc. to develop a nanoparticle formulation of a mediator kinase inhibitor drug candidate, SNX631-6, for the treatment of peritoneal ovarian cancer metastases. The goal is to optimize the nanoparticle formulation for improved pharmacokinetics and efficacy compared to oral administration when delivered intraperitoneally. The project will assess the...